Our Mission

At DavosPharma, our mission is to be the trusted partner for small to mid-sized biotech companies, guiding them through the complexities of drug development and outsourcing.

We provide an integrated, end-to-end solution that streamlines the CMC process, reducing risk and accelerating timelines.

Our expertise in sourcing, regulatory compliance, and manufacturing ensures that our clients benefit from the same level of service and negotiation power as large pharmaceutical companies.

By leveraging a carefully vetted global network of CDMOs and CROs, we deliver cost-effective solutions with best-in-class reliability.

Our History

In 1972, H. Barry Robins established DavosPharma with the idea of bridging the gaps between petrochemical and specialty chemical companies. Not long after, he recognized the challenges biotech and pharmaceutical companies face in navigating global outsourcing and supply chain.

DavosPharma pioneered a model that provides clients with the benefits of a large customer, regardless of their project size. Over the past five decades, the company has built a reputation for its expertise, ensuring that clients receive high-quality service from trusted global partners.

DavosPharma has played a pivotal role in the success of multiple INDs and NDAs. Today, the company continues to expand its global network, maintaining a commitment to excellence and risk mitigation in drug development outsourcing.

Meet Our Team

Custom chemistry, biology and formulation is our business.

H. Barry RobinsFounder - Chairman of the Board
H. Barry Robins founded DavosPharma in 1972. He started his business career with ICI, Canada as a Process Engineer. Mr. Robins then worked for ICC, New York, where he held the position of Vice President, Marketing. Mr. Robins holds a B.Sc. in Chemical Engineering from Queens University, Kingston, Ontario.
Brian S. RobinsCo - CEO
Brian Robins joined DavosPharma in 1994. He focused on a number of multinational and emerging pharmaceutical companies, developing six clinical candidates. Three of these NCE projects are in late Phase III clinical trials, and one is awaiting FDA approval. Prior to joining DavosPharma, Mr. Robins worked at Delmar Chemical in Montreal. Mr. Robins holds a B.Sc. in Chemical Engineering from Queen’s University, Kingston, Ontario.
David A. RobinsCo - CEO
David Robins has been instrumental in expanding DavosPharma from strictly manufacturing and marketing of small molecule building blocks for active substances to a full service provider. Under his leadership, DavosPharma now supports all manufacturing, biology and regulatory needs for commercial and IND drug development. Prior to joining Davos, Mr. Robins was a lead Process Engineer at Bristol-Myers Squibb where he was responsible for the scale up and tech transfer of several late stage and commercial drugs. Mr. Robins received his B.S. in Engineering Chemistry from Queen’s University in Kingston, Ontario and M.S. in Chemical Engineering from Syracuse University.
Anthony DelPreteExecutive Vice President and Chief Financial Officer
Anthony DelPrete’s primary responsibilities include the ongoing development and risk management of DavosPharma’s financial operations’ strategy. He manages all aspects of the company’s finances and internal operations, including confidentiality agreements (CDAs), contract negotiations, legal and insurance matters. Mr. DelPrete began his career with DavosPharma in 1982. He holds a B.A. in Marketing from Pace University and a M.B.A. in Finance from Iona College.
Suzanne EpsteinBusiness Manager
Suzanne Epstein has been with Davos for 17 years. Her main job function today includes managing and reviewing confidential disclosure agreements, master services agreements and supply agreements. She also assists the field sales representatives their daily roles. Prior to joining Davos, Ms. Epstein was a technical sales representative for Witco Corporation and bench chemist at Sun Chemical. She has a Bachelor of Science and Natural History from Muhlenberg College and a Master’s of Business Administration in Marketing from Montclair State University.
George T. GeorgesExecutive Vice President of Sales
George Georges joined DavosPharma in 2013. He is responsible for business development in the New England area. Prior to joining DavosPharma, Mr. Georges was a Global Account Manager for Avantor Performance Materials (formerly Mallinckrodt Baker) for ten years. In his role, he managed the cGMP Pharma chemicals portfolio at a number of large BioPharma accounts and many biotech startups in the Boston area. Before joining Avantor, Mr. Georges started his career in nanotechnology at Triton Systems managing SBIR programs on high performance coatings and barrier polymers. Mr. Georges earned his B.S. in Chemistry from the University of Massachusetts, Amherst and an MBA from Babson College.
Matt CwiklinskiDirector, Business Development
Matt Cwiklinski joined DavosPharma in 2019. His responsibilities include developing new business in Southern California and the Midwest. Prior to joining Davos, he spent 12 years developing new customers for Olon Ricerca (formerly Ricerca Biosciences), Apiscent Labs, LLC (formerly Fontarome Chemical), and Cambridge Major Laboratories (now part of Sterling Pharma). During these years, he developed relationships with emerging biotech to large multi-national pharma clients to bring their APIs from concept to commercial. Prior to Business Development, Matt spent 10 years performing process development, scale up, and cGMP manufacturing with Cambridge Major Laboratories. Matt received his B.S. in Chemistry from the University of Minnesota – Twin Cities.
Conor HoulihanLogistics Coordinator
Conor Houlihan joined DavosPharma in 2017. He is responsible for the internal support of import/export logistics and database management. He holds a B.S. in Chemical Engineering from the State University at Buffalo.
Michael KatesVP, Integrated IND/NDA Program Development
Dr. Michael Kates joined DavosPharma in 2011. He is responsible for business development and management of Davos’ fully Integrated Drug Discovery Service Platform. Prior to this, he worked as a medicinal chemist at both Wyeth Laboratories and DuPont-Merck. He holds a B.S. degree in chemistry, a Ph.D. from Villanova University and Post Doctorial Research Fellow at Brown University. Dr. Kates is an Adjunct Associate Professor Medicinal Chemistry at the University of New England, School of Pharmacy and has 21 publications and contributed talks.
Vance LyonSenior Director
​Dr. Lyon joined DavosPharma in 1998. He is responsible for project management and new business development of custom chemistry resources for both emerging and multinational pharmaceutical companies. ​Prior to joining DavosPharma, Dr. Lyon was Director of Analytical Services and Quality Assurance at Chemir Polytech Laboratories and Director of Marketing and QA at Parish Chemical. Dr. Lyon holds a Ph.D. in Synthetic Organic Chemistry from the University of Utah and a B.S. from the University of Chicago.
Greg BydlinskiDirector, Chemistry - Montreal, Canada
Greg Bydlinski joined DavosPharma in 2016. He is responsible for business development in Canada while providing technical support in the New England area. Prior to joining DavosPharma, Dr. Bydlinski was a Business Development Manager/R&D Director/R&D Supervisor/Senior Scientist with Delmar Chemicals, Montreal over a period of twenty years. Dr. Bydlinski started his process chemistry career in 1987 at Ciba-Geigy, Summit, NJ. Dr. Bydlinski earned his BA in Chemistry and Psychobiology from Hamilton College, Clinton, NY. Subsequently, he earned his MSc and PhD from Emory University, Atlanta, GA.
Lucja OrzechowskiProject Manager
Lucja Orzechowski joined DavosPharma in January 2017. Her primary role is to monitor activities to ensure timely delivery of goods, reports and project-related data. Prior to joining Davos she worked as a Medicinal Chemist at Roche and was a Quality Assurance Auditor at Lohmann Therapy Systems. She holds a B.S. degree in Food Science from Lodz University of Technology in Poland and a M.S. in Organic Chemistry from Montclair State University.
Muppala S. RajuVice President, Chemistry
Dr. Muppala Raju joined DavosPharma in 1995. He is responsible for the development of DavosPharma’ business activities in India. Dr. Raju is also head of chemistry at DavosPharma where he directs the process development of all contracted projects at DavosPharma’ worldwide custom manufacturers. Prior to joining DavosPharma, Dr. Raju held several positions including Manager of Chemical Process R&D for Celgene Corporation. He was also a Research Scientist for Rhône-Poulenc Research Center, Research Chemist for PPG Industries and held post doctoral positions at the University of Iowa and Rockefeller University. Dr. Raju has co-authored fifteen research publications and has been issued six patents. He holds a Ph.D. from Rice University and an MBA from Kent State University.
Michael E. ShoreDirector, Project Management & API Development - San Francisco, CA
Micheal Shore joined DavosPharma in 2007. He is responsible for business development with the emerging biotech and pharmaceutical companies in the Bay Area and Pacific Northwest. Prior to DavosPharma, Mike began his career with Ciba-Geigy as a process chemist. He then joinied Agouron Pharmaceuticals/WarnerLambert/Pfizer where he was responsible for process development, scale-up, optimization, technology transfer, validation and the manufacture of Viracept®, Agouron’s small molecule protease inhibitor. Mr. Shore has also worked at Amylin Pharmaceuticals as a Project Manager. Mr. Shore holds a B.S. degree in Organic Chemistry from Florida State University. He has also had direct involvement with the filing of six INDs and two NDAs.
Shobhana SridharanTechnical Sales Coordinator
Shobhana Sridharan joined the DavosPharma in 2005. Her responsibilities include inside sales and database management. She holds an M.S. in Food and Nutrition from Women’s University in India.

We Deliver

Whether your company has ten employees or ten thousand, DavosPharma has the resources and energy to deliver the discovery, toxicology, biologics, chemistry, and formulation services you need.